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sor genes (TSGs) human mismatch repair protein homologue
1 (hMLH1), AP20 region gene 1 (APRG1), integrin a RLC (ITGA9),
RB1 serine phosphates from human chromosome 3 (RBSP3) at chro-
mosomal 3p22.3 region and development of head and neck
squamous cell carcinoma (HNSCC), alterations (deletion ⁄promoter
methylation ⁄ expression) of these genes were analyzed in 65 dys-
plastic lesions and 84 HNSCC samples. Clinicopathological correla-
tions were made with alterations of the genes. In HNSCC, deletion
frequencies of hMLH1, ITGA9, and RBSP3 were comparatively
higher than APRG1. Overall alterations (deletion ⁄methylation) of
hMLH1, ITGA9, and RBSP3 were high (45–55%) in mild dysplasia
and comparable in subsequent stages of tumor progression. Quan-
titative RT-PCR analysis showed reduced expression of these genes
in tumors concordant to their molecular alterations. An in vitro
demethylation experiment by 5-aza-2¢-deoxycytidine confirmed
the promoter hypermethylation of RBSP3 in Hep2 and UPCI:SCC084
cell lines. Functionally less-active RBSP3A isoform was predomi-
nant in tumor tissues contrary to the adjacent normal tissue of
tumors where more active RBSP3B isoform was prevalent. In
immunohistochemical analysis, intense nuclear staining of hMLH1
and pRB (phosphorylated RB, the substrate of RBSP3) proteins
were seen in the basal layer of normal epithelium. In tumors, con-
cordance was seen between (i) low ⁄ intermediate level of hMLH1
expression and its molecular alterations; and (ii) intense nuclear
staining of pRB and RBSP3 alterations. Poor patient outcome was
seen with hMLH1 and RBSP3 alterations. Moreover, in absence of
human papilloma virus (HPV) infection, tobacco-addicted patients
with hMLH1, RBSP3 alterations, and nodal invasions showed poor
prognosis. Thus our data suggests that dysregulation of hMLH1,
ITGA9, and RBSP3 associated multiple cellular pathways are
needed for the development of early dysplastic lesions of the head
and neck. (Cancer Sci 2010; 101: 1511–1520)
H ead and neck squamous cell carcinoma (HNSCC)accounts 30–40% of all cancer types in the Indian subcon-
tinent and is associated with prolonged tobacco habit, alcohol
abuse, and human papilloma virus (HPV) infection, particularly
types 16 and 18.(1) Despite improvements in treatment modali-
ties, HNSCC is associated with high rates of recurrence and
mortality and 5-year survival rates remain around 50%.(2) If
identified early, the prognosis of HNSCC is excellent, so the
implication of being able to classify genetic alterations during
tumor progression is significant.(3) In a microcell hybrid system,
there was evidence of suppression of tumorigenicity of oral can-
cer cell lines following introduction of chromosome (chr.) 3p,
suggesting the presence of at least one tumor suppressor gene
(TSG) in the chromosomal arm.(4) In a preliminary tumor pro-doi: 10.1111/j.1349-7006.2010.01551.x
ª 2010 Japanese Cancer Associationgression model of HNSCC, allelic loss in chr. 3p was suggested
to be associated with the transition of hyperplasia to dysplasia.(2)
Our previous study on HNSCC of Indian patients showed multi-
ple deletions in chr.3p that were differentially associated with
the tumor development.(5) Among these deleted regions, chr.
3p22.3 (http://www.ensembl.org, Release 49, March 2008)
harbors multiple candidate TSGs viz. human mismatch repair
protein homologue 1 (hMLH1), AP20 region gene 1 (APRG1),
integrin a RLC (ITGA9), RB1 serine phosphates from human
chromosome 3 (RBSP3) within about 1Mb region. The associa-
tion of these genes together with HNSCC development has not
been studied well.
The mismatch repair gene (MMR) hMLH1 is involved in
repair of DNA mispairing incorporated during replication.(6)
Deletion and promoter hypermethylation of hMLH1 was reported
in HNSCC and in other tumors.(5,7–9) However, alteration of
hMLH1 in HNSCC along with its expression (RNA ⁄ protein)
during tumor progression has not yet been studied.
The APRG1 gene located 0.4 Mb centromeric to hMHL1 has
been implicated in cell membrane interactions and cell adhe-
sion.(10) Homozygous deletion of APRG1 was reported in major
epithelial malignancies.(10) ITGA9 located 0.4 Mb further down-
stream of APRG1 encodes the integrin a9 subunit of the hetero-
dimer a9b1 that binds to a variety of ligand molecules like
osteopontin, vascular cell adhesion molecule-1, disintegrin, etc.
to control cell division, spreading, differentiation, and migration,
etc.(11–13) Molecular alterations of ITGA9 have not yet been
studied in HNSCC although its reduced expression was reported
in oral cancer.(14) Closely linked to ITGA9 (190 kilobase centro-
meric), RBSP3 is an important candidate TSG with reported
tumor suppressive ability in vitro and in vivo.(15) RBSP3 encodes
a protein phosphatase that dephosphorylates retinoblastoma pro-
tein RB at serine 807 ⁄811, presumably halting the cell at the G1-
S boundary of cell cycle, thereby controlling proliferation.(15)
There exists two splice variants of RBSP3, the larger RBSP3B
form retains all exons of the gene, while the smaller RBSP3A
form lacks the third exon (33bp, coding for 11 amino acids).
Although both the isoforms have been reported to suppress
tumor growth in vivo and in vitro, RBSP3A has lower suppres-
sion activity than that of RBSP3B.(15) The prevalence of the two
isoforms of RBSP3 has not been studied in any tumors. Deletion
and promoter hypermethylation of RBSP3 was reported in breast
carcinoma.(8) However, molecular alteration of RBSP3 was not
analyzed in HNSCC, and also functional relevance of the gene in
dephosphorylation of pRB (phosphorylated RB) at serine
807 ⁄811 in any tumor development has not been not studied.Cancer Sci | June 2010 | vol. 101 | no. 6 | 1511–1520
Thus in the present study, attempts have been made to under-
stand the association between hMLH1, APRG1, ITGA9, and
RBSP3 and the development of HNSCC. The alterations (dele-
tion ⁄promoter methylation ⁄ expression) of these genes were
analyzed in dysplastic lesions of the head and neck, primary
HNSCC samples and four HNSCC cell lines (Hep2, KB,
UPCI:SCC084, and UPCI:SCC131). To assess the inactivation
of RBSP3 during HNSCC development, the expression of phos-
phorylated of RB at serine 807 ⁄811 was analyzed by immuno-
histochemistry in primary head and neck lesions and the two
cell lines. The molecular alterations were then correlated with
various clinicopathological parameters and with disease recur-
rence ⁄ death. In this study, our results showed the association of
candidate genes MLH1, ITGA9, and RBSP3 with the develop-
ment of early dysplastic lesions of the head and neck.
Materials and Methods
Patients, tumor tissues, and cell lines. A total of 149 primary
head and neck lesions and corresponding normal area ⁄peripheral
blood leukocytes were collected from Chittaranjan National
Cancer Institute and Cancer Center & Welfare Home, Kolkata,
India, from 147 unrelated individuals from 1998 to 2008.
Informed consent from patients and approval from the Research
Ethics Committee of the institute were obtained. Samples were
frozen immediately after collection at )80C until use. Part of
the freshly operated tissues was directly collected in TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) for RNA isolation and
another part was embedded in paraffin for immunohistochemis-
try. Detailed clinicopathological histories of patients are pre-
sented in Table 1. Among HNSCC cell lines, Hep2 and KB
were procured from the National Centre for Cell Sciences, Pune,Table 1. Clinicopathological features of head and neck lesions
Clinical features Patient no. (n = 149) Median age (years
Primary site
Orofacial (%) 13 (9) 39
Oral cavity (%) 127 (85) 48
Larynx (%) 9 (6) 58
Tumor stage†
Dysplasia (n = 65)
Mild (%) 18 (28) 44
Moderate (%) 27 (41.5) 45
Severe (%) 20 (31) 50
HNSCC (n = 84)
Stage I (%) 10 (12) 45
Stage II (%) 23 (27) 60
Stage III (%) 27 (32) 50
Stage IV (%) 24 (29) 50
Gender
Male (%) 113 (76) 50
Female (%) 36 (24) 45
Tumor differentiation
Well (%) 40 (48) 52
Moderate (%) 32 (38) 50
Poor (%) 12 (14) 50
Lymph Node
Node+ (%) 28 (33) 50
Node) (%) 56 (67) 52
Tobacco
Tobacco+‡ (%) 93 (62) 48
Tobacco) (%) 56 (38) 46
†According to International Union Against Cancer (UICC) TNM classificatio
amount of chewable tobacco per day for at least 10 years. HNSCC, head a
1512India, while UPCI:SCC084 and UPCI:SCC131 were kindly pro-
vided by Professor Susanne M. Gollin, University of Pittsburgh,
Pittsburgh, PA, USA.
Microdissection and DNA extraction. The procedure is
described in detail in the Supporting Information.
Deletion analysis of candidate genes by microsatellite
markers. Deletion analysis of the candidate genes hMLH1,
APRG1, ITGA9, and RBSP3 were done by five microsatellite
markers located in and around these genes (Fig. 1A, Supporting
Information Table S1a), in 65 dysplastic lesions, 84 HNSCC
samples, and four HNSCC cell lines. The markers were selected
on the basis of their map positions (Ensemble release 49; Gen-
ome Database). All the markers showed informativeness >60%
in our samples (data not shown), except D3S3880 and D3S4237.
The deletion mapping procedure is described in detail in the
Supporting Information (see Fig. S1 also for information of STS
markers used here).
Deletion analysis of candidate genes by Southern blot
analysis. The ITGA9 and RBSP3 loci were physically mapped
in 48 HNSCC samples, of which 22 were studied by microsatel-
lite markers (D3S3880 and D3S4237) as well. The procedure is
described in detail in the Supporting Information.
PCR-based methylation-sensitive restriction analysis (MSRA). The
methylation status of hMLH1, ITGA9, and RBSP3 promoters was
screened in 54 dysplastic lesions, 66 HNSCC samples, and four
HNSCC cell lines by MSRA(16) using primers as mentioned in
Supplementary Table S1(b). The procedure is described in detail
in the Supporting Information. (See Fig. S1 also for information
of STS markers used here).
mRNA expression analysis. Total RNA was isolated from
samples using TRIzol reagent according to the manufacturer’s
protocol. The cDNA was synthesized by Superscript III) Age (years)
HPV 16 ⁄ 18 positivity
HPV+ HPV) P-value
22–76 6 (46.1) 7 (53.8) 0.203
30–74 61 (48) 66 (52)
50–75 7 (77.7) 2 (22.2)
0.001
30–60 6 (33) 12 (67)
25–52 9 (33) 18 (67)
22–70 9 (45) 11 (55)
33–70 4 (40) 6 (60)
32–74 12 (52) 11 (48)
58–62 19 (70) 8 (30)
30–75 15 (63) 9 (37)
22–76 54 (48) 59 (52) 0.416
30–65 20 (56) 16 (44)
22–76 18 (45) 22 (55) 0.001
34–65 22 (69) 10 (31)
32–75 11 (92) 1 (8)
30–70 15 (54) 13 (46) 0.431
22–76 35 (63) 21 (37)
30–75 40 (43) 53 (57) 0.036
22–76 34 (60) 22 (39)
n (excluding dysplasia). ‡Ten to 15 cigarettes ⁄ bidis or equivalent
nd neck squamous cell carcinoma; HPV, human papilloma virus.
doi: 10.1111/j.1349-7006.2010.01551.x
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Fig. 1. (A) Schematic map of 3p22.3 region with microsatellite and sequence tag site (STS) markers used in this analysis: dark lines (D1, D2)
indicate deleted regions identified in our study. (B) Autoradiograph showing loss of heterozygosity (LOH), microsatellite size alteration of one
allele (MA-I), and loss of one allele and size alteration of the other (LOH + MA) (a). › indicates loss of corresponding alleles and indicates size
alteration of one or both alleles. Homozygous ⁄ hemizygous deletion (HD\HED) of RB1 serine phosphates from human chromosome 3 (RBSP3) and
integrin a RLC (ITGA9) loci (b). (C) Representative autoradiographs of Southern hybridization showing homozygous (HD) and hemizygous (HED)
deletions of RBSP3 and ITGA9 loci. CD3c was used as a control locus. Marker, k HindIII marker; ›, allelic loss. (D) Histogram showing genetic
alterations of the 3p22.3 region in head and neck squamous cell carcinoma (HNSCC) (a) and dysplastic lesions (b); D1 and D2 are highly deleted
regions. N, DNA from normal tissue ⁄ peripheral blood lymphocyte (PBL); T, tumor DNA.(Invitrogen) reverse transcriptase, and semiquantitative RT-PCR
analysis was performed using specific primers (Table S1c) for
hMLH1, ITGA9, and RBSP3 along with b2-microglobulin as an
endogenous control.(17) Real-time quantification of the genes
was performed using SYBR-green PCR assay in four HNSCC
cell lines (Hep2, KB, UPCI:SCC084, and UPCI:SCC131), 22
primary HNSCC samples, and their adjacent normal tissues (see
Supporting Information for further details). The expression pat-
tern of RBSP3 isoforms was studied in same set of samples as
described above, by semi-quantitative RT-PCR using specific
primer sets (Table S1c). b2-Microglobulin was taken as the
endogenous control.(17) The PCR product was electrophoresed
on 2% agarose gels, visualized by ethidium bromide staining,
and quantitated with the Gel Documentation system (GS-800;
Bio-Rad, Hercules, CA, USA).
To confirm inactivation of candidate TSGs by promoter
hypermethylation, the mRNA expression of these genes was
studied in Hep2 and UPCI:SCC084 cell lines in presence andGhosh et al.absence of 5-aza-2¢-deoxycytidine (5-aza-dC), a drug that inhib-
its DNA methylation. A subconfluent culture of the cell lines
were grown in presence of 10 lM and 20 lM 5-aza-dC and in
absence of 5-aza-dC (control) separately for 5 days. RNA was
prepared and RT-PCR (semiquantitative and quantitative) of the
genes was performed as described in the Supporting Information.
Expression analysis of candidate TSGs by immunohisto-
chemistry. The immunohistochemical analysis of hMLH1 and
pRB (phosphorylated RB) was done using the standard staining
kit according to the manufacturer’s protocol (Santa Cruz Bio-
technology, Santa Cruz, CA, USA). Immunostaining of pRB
protein was done to understand the functional importance of
RBSP3 with respect to removal of phosphate group from serine
807 ⁄811 of pRB. The procedure is described in detail in the
Supporting Information.
Detection of HPV-16/18. Presence of HPV-16 ⁄ 18 in the head
and neck lesions was detected by PCR using primers (MY09
and MY11) from the consensus L1 region followed by HPVCancer Sci | June 2010 | vol. 101 | no. 6 | 1513
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(A) (B)
Fig. 2. Promoter methylation analysis of candidate
genes by methylation-sensitive restriction analysis
(MSRA). (A) Representative samples showing
methylation status of the genes. Tumor (T) and
normal (N) DNA were restriction-digested by
methylation insensitive restriction enzyme (MSP1)
and HpaII; Moc, no digestion. K1 and K2, DNA
digestion and integrity controls respectively. (B)
Methylation frequencies of the candidate genes
observed in our study.
Fig. 3. (A) Quantitative RT-PCR analysis of mRNA expression of the candidate genes. Bars represent fold reduction of mRNA expression of the
candidate genes. (B) Semi-quantitative (a) and quantitative RT-PCR (b,c) analysis of mRNA expression of the candidate genes in Hep2 and
UPCI:SCC084 cell lines. Bars represent increase of fold expression of the respective genes in 5-aza-2¢-deoxycytidine (5-aza-dC) treatment
compared to the untreated control.16 ⁄18 typing in the L1-positive samples as described previ-
ously.(5)
Statistical analysis. Fisher’s exact test was used to determine
the association between the genetic profile of tumors and differ-
ent clinicopathological features. P-values £0.05 were consid-
ered statistically significant. The Kaplan–Meier method and
Cox proportional hazards regression model were used to predict
the overall survival status of the patients (see Supporting
Information for further details). All the statistical analysis was
performed using the statistical program SPSS (SPSS, Chicago,
IL, USA).1514Results
Deletion analysis of candidate TSGs. Microsatellite-based
deletion analysis of about 1 Mb chr. 3p22.3 region showed 52%
(77 ⁄149) overall chromosomal alterations (deletion ⁄microsatel-
lite size alteration) in the primary head and neck lesions in at
least one of the markers, indicating the importance of this region
in the development of HNSCC (Fig. 1). Two discrete regions of
high deletion (D1 and D2) at 0.8 Mb apart were identified. The
D1 region (D9S1611 and D9S1007) harboring the candidate
gene hMLH1 was deleted in 14% of dysplastic lesions and 39%doi: 10.1111/j.1349-7006.2010.01551.x
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of HNSCC samples. The D2 region harbors two candidate TSG
loci, that is ITGA9 (D3S3880) and RBSP3 (D3S4237) with 24%
deletion each in dysplastic lesions and 25% and 32% deletion in
HNSCC samples, respectively. About 0.4 Mb centromeric to the
hMLH1, a candidate TSG APRG1 was localized. But the micro-
satellite markers D3S3623 closely linked to this candidate gene
showed only 17% (12 ⁄70) deletion in HNSCC samples. Thus, it
seemed that APRG1 might not be associated with the develop-
ment of HNSCC.
The markers intragenic to hMLH1 showed 3–5% microsatte-
lite size alteration (MA) in HNSCC samples and dysplastic
lesions, while biallelic alterations (LOH+MA) were noted in 3%
of HNSCC samples only. On the other hand, homozygous dele-
tion was found in ITGA9 and RBSP3 loci in 5% (4 ⁄80) and 4%
(3 ⁄85) of HNSCC samples, respectively. Among HNSCC cell
lines, hemizygous deletions of ITGA9 and RBSP3 were found in
UPCI:SCC084 and KB, respectively.
In physical mapping by Southern blot analysis, ITGA9 and
RBSP3 showed 17% (8 ⁄ 48) and 27% (13 ⁄48) deletion, respec-
tively. Rare homozygous deletion was found in about 4%
(2 ⁄48) of samples for ITGA9 and in about 2% (1 ⁄48) for
RBSP3. Concordance was seen between microsatellite-based
deletion mapping and physical mapping in 82% (P = 0.05) sam-
ples for ITGA9 and 86% (P = 0.002) samples for RBSP3 of 22
common primary tumors analyzed by both techniques
(Table S2).
Promoter methylation status of candidate TSGs. In dysplastic
lesions hMLH1 showed high frequency (46%) of promoter
methylation followed by RBSP3 (39%) and ITGA9 (24%); how-
ever, in HNSCC samples comparable methylation (29–38%)
was seen in these genes (Fig. 2). Among HNSCC cell lines,
Hep2 and UPCI:SCC084 showed methylated promoter for(A)
(B)
(C)
Fig. 4. (A) Schematic diagram of the RBSP3 gene and two RBSP3 isoform
reverse primers used in expression analysis. (B) Relative mRNA expression o
its two isoforms RBSP3A and RBSP3B. Primers FP and RP1 were used to fo
of RBSP3 isoforms. N, corresponding normal; T, RNA from tumor samples.
(RBSP3B ⁄ RBSP3A) in tumor and adjacent normal tissues of the respective s
Ghosh et al.RBSP3, while ITGA9 methylation was found in KB and
UPCI:SCC131.
Interrelationship between molecular alterations of candidate
TSGs. In hMLH1, both deletion and methylation were seen in
22% (24 ⁄110) of samples analyzed followed by RBSP3 (12%,
13 ⁄110) and ITGA9 (5%, 6 ⁄110) (data not shown). Deletion
and methylation of ITGA9 showed significant association
with that of RBSP3 in dysplastic lesions and HNSCC samples
(Table S3a,b). Overall molecular alterations to these genes also
showed significant trend of association (Table S3c).
mRNA expression analysis. In quantitative RT-PCR, the fold
reduction (mean value) of expression of the candidate TSGs in
the primary tumors with respect to their control was in the
following order: ITGA9 (34.2 ± 5.0) > hMLH1 (33.8 ± 3.9) >
RBSP3 (33.6 ± 9.4) (Fig. 3A). Reduced expression of all three
candidate TSGs was found in the UPCI:SCC084 cell line, two in
KB (ITGA9 and RBSP3) and one in each of Hep2 (RBSP3) and
UPCI:SCC131 (ITGA9). However, after 5-aza-dC treatment of
Hep2 and UPCI:SCC084 cell lines, only RBSP3 showed consid-
erable activation of its expression (20–22-fold) in comparison to
other genes.
In normal head and neck tissues, RBSP3B was more predom-
nantly expressed than RBSP3A (Fig. 4). Out of 22 HNSCC
samples analyzed, RBSP3 expression was undetectable in 10
samples and was not altered in four samples. In the rest of the
eight samples, RBSP3A was preferentially expressed over
RBSP3B, though total RBSP3 expression was more or less con-
stant. In HNSCC cell lines, altered expression pattern of RBSP3
isoforms was found in UPCI:SCC131 (Fig. 4, Supporting Infor-
mation Fig. S2).
Immunohistochemical analysis of pRB (total ⁄phosphorylated)
and hMLH1. Immunohistochemical analysis of normals. 1–8, exons of the respective gene. FP, forward primer; RP1 and RP2,
f total RB1 serine phosphates from human chromosome 3 (RBSP3) and
r detection of total RBSP3 while primers FP and RP2 used for detection
(C) Histogram showing comparism of expression of the RBSP3 isoforms
amples.
Cancer Sci | June 2010 | vol. 101 | no. 6 | 1515
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(A)
(B)
(a)
(b)
(a) (b)
Fig. 5. Immunohistochemical staining patterns of human mismatch repair protein homologue 1 (hMLH1), and phosphorylated RB (pRB) in head
and neck squamous cell carcinoma (HNSCC) cell lines (A) and head and neck tissues (B). L, leukoplakia ⁄ dysplastic lesions; N, normal tissue;
T, HNSCC samples. Arrow indicates the expression pattern of the corresponding proteins.epithelium-localized hMLH1 protein in the nucleus of basal
cells (Fig. 5). Low ⁄ intermediate level of diffuse nuclear staining
of hMLH1 was found in 64%(18 ⁄28) of head and neck lesions
(Table 2a). In HNSCC cell lines, expression of hMLH1 was
mainly nuclear except Hep2, where weak cytosolic expression
was seen along with few cells with nuclear expression. In
UPCI:SCC084, weak hMLH1 expression was seen in the
nucleus (Fig. 5, Fig. S3). Concordance was seen between
molecular alterations and mRNA ⁄protein expression.
In normal epithelium, immunostaining revealed intense
nuclear expression of pRB (phosphorylated) in the basal layer
and during differentiation its expression gradually decreased
(Fig. 5). High ⁄ intermediate level of nuclear staining of pRB
(phosphorylated) was seen in 82% (23 ⁄28) of head and neck
lesions where deletion and ⁄or methylation or splice variation of
RBSP3 was present (Table 2b). Similarly intense nuclear stain-
ing (high ⁄ intermediate) of pRB (phosphorylated) was also seen
in four HNSCC cell lines (Fig. 5, Fig. S3). A low level of pRB
(phosphorylated) expression was recorded in 18% (5 ⁄28) of
head and neck lesions of which deletion of Rb locus was
detected in three samples (data not shown).
In expression analysis, seven among 14 and three among nine
HPV-positive samples showed reduced expression of hMLH1
(RNA ⁄ protein) and RBSP3 (RNA) respectively due to their
molecular alterations.
Detection of HPV. Using L1 primer, HPV-DNA was detected
in 50% (74 ⁄149) of the head and neck lesions. Among HPV-
positive samples, 94% (70 ⁄74) were HPV16 positive and 6%
(4 ⁄74) were HPV18 positive. Among HNSCC cell lines, Hep2
and KB were HPV18 positive, whereas in the other two no HPV
infection was detected. HPV infection was found to be inversely
correlated with tobacco consumption. However, positive corre-1516lation of HPV infection was found with tumor stage and tumor
differentiation, suggesting its association with the disease pro-
gression (Table 1).
Clinicopathological association and patient survival. In mild
dysplastic lesions, RBSP3 and ITGA9 showed high frequency of
deletion (22–28%) and became comparable in the subsequent
stages of tumor progression (Fig. 6A). On the other hand, no
hMLH1 deletion was seen in mild dysplastic lesions but during
tumor progression its deletion frequency gradually increased
and became maximum (50%) at stage III ⁄ IV (P = 0.003). How-
ever, in mild dysplastic lesions methylation frequency of
hMLH1 and RBSP3 was higher (44–38%) than ITGA9 (22%)
and did not change significantly in subsequent stages of tumor
progression. Interestingly, the overall alterations (dele-
tion ⁄methylation) of hMLH1, ITGA9, and RBSP3 were high
(45–55%) in mild dysplastic lesions and remained more or less
constant with disease progression. Alterations of hMLH1
showed significant correlation with tobacco habit in both dys-
plastic lesions (P = 0.007) and HNSCC samples (P = 0.0003),
whereas inverse correlation was seen between alterations of
hMLH1 ⁄RBSP3 and HPV infection in dysplastic lesions
(Table S4). Patients with hMLH1 alterations and RBSP3 altera-
tions showed significant poor survival by log-rank test (Fig. 6B).
Multivariate analysis using the Cox proportional hazard model
showed that tobacco addiction (P = 0.008; HR = 7.39; 95%
confidence interval [CI], 1.68–33.08) along with alterations to
hMLH1 (P = 0.027; HR = 5.88; 95% CI, 1.2–28.5) and RBSP3
(P = 0.046; HR = 12.5; 95% CI, 1.04–49.5), and nodal invasion
(P = 0.027; HR = 5.88; 95% CI, 1.2–28.5) in absence of HPV
infection (P = 0.0014; HR = 0.118; 95% CI, 0.03–0.43) were
significant predictors of hazardous life and poor survival in
HNSCC patients (Table 3).doi: 10.1111/j.1349-7006.2010.01551.x
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Table 2. (a) Comparison of hMLH1 expression with respect to its
alterations. (b) Comparison of pRB expression with respect to
molecular alterations and expression of RBSP3
HPV status RNA (Q.PCR) Protein ALT.
(a)
HNSCC cell lines
Hep2 HPV+ )1.5 High –
SCC084 HPV) )10 Low –
KB HPV+ )1.6 High –
SCC131 HPV) )1.1 High –
Dysplastic lesions
L127 HPV+ ND Intermediate –
L154 HPV) ND Low M+
L139 HPV+ ND High –
L162 HPV+ ND High –
L158 HPV) ND Low M+
L117 HPV) ND Intermediate M+
L150 HPV+ ND Low D+M+
L132 HPV) ND High –
L153 HPV) ND Low D+
L143 HPV+ ND Intermediate M+
HNSCC samples
1004 HPV+ )37 Low D+M+
5165 HPV+ )1.71 High –
6817 HPV+ )1 High –
2884 HPV+ )31 Low M+
1108 HPV) 1.5 High –
1774 HPV+ )36 Low D+
872 HPV) )40 Low D+
5303 HPV) )34 Low M+
6907 HPV) )32 Low D+M+
1087 HPV+ )1.9 High –
944 HPV) )32 Intermediate M+
5733 HPV+ )1.4 High –
6392 HPV) 1.43 High –
7077 HPV+ )30 Intermediate M+
797 HPV+ )38 Low D+M+
4271 HPV) )39 Low D+M+
5488 HPV) )25 Low M+
4345 HPV) )1.7 High –
P-value 0.0000006
pRB Protein
RBSP3
ALT. RNA (Q.PCR)
(b)
HNSCC cell lines
Hep2 High M+ )10
SCC084 High M+ )24
KB Intermediate D+ )42
SCC131† High – )1.8
Dysplastic lesions
L127 High – ND
L154 High D+ ND
L139 High D+ ND
L162 High D+ ND
L158 Intermediate M+ ND
L117 High M+ ND
L150 Low – ND
L132 High D+ ND
L153 High M+ ND
L143 Low – ND
HNSCC samples
1004 High – 1.21
5165 High D+ )41
6817† Intermediate – )1.8
Table 2. (continued)
pRB Protein
RBSP3
ALT. RNA (Q.PCR)
2884 High – )1.2
1108 Low – )1
1774† Intermediate – )1.5
872 High D+ )32
5303 High D+M+ )40
6907 High M+ )32
1087 High D+ )42
944† Intermediate – )1.97
5733 High M+ )45
6329† High – )10
7077 High – 1.4
797† High – )1.31
4271 Low – )31
5488 Low – )1.3
4345 High M+ )30
P-value 0.009
Q.PCR, quantitative real-time RT-PCR; each value represents fold
reduction of relative RNA level in tumor versus corresponding
non-tumor tissues. †Samples showing altered splicing pattern of
RBSP3 transcripts. –, no alterations; ALT., alterations; D+, Deletion
positive; hMLH1, human mismatch repair protein homologue 1;
ITGA9, integrin a RLC; HNSCC, head and neck squamous cell
carcinoma; HPV, human papilloma virus; HPV), HPV negative; HPV+,
HPV positive; M+, Methylation positive; ND, not done; RBSP3, RB1
serine phosphates from human chromosome 3.
Ghosh et al.Discussion
In this study, high frequency of molecular alterations (deletion ⁄
promoter methylation) and concordant reduced expression of
hMLH1, ITGA9, and RBSP3 suggested them to be candi-
date TSGs for the development of HNSCC. High frequency of
alterations to these genes in mild dysplastic lesions suggested
their involvement at the early stage of head and neck tumor-
igenesis. To the best of our knowledge, no such study has been
previously reported.
The deletion and ⁄or methylation of closely linked ITGA9 and
RBSP3 showed significant association in both dysplastic lesions
and HNSCC samples, whereas no such association was seen
with that of hMLH1. This indicates that alterations of hMLH1
and RBSP3 ⁄ ITGA9 are independent events. Though the major-
ity of the samples showed coalterations of RBSP3 and ITGA9,
in some samples alterations of only ITGA9 or RBSP3
(Table S3c) were seen suggesting their alterations were not due
to epiphenomena. It seems that alterations of these genes could
have a synergistic role in development of the early dysplastic
lesions of the head and neck. Interestingly, the inverse associa-
tion seen between alterations of hMLH1 and RBSP3 and HPV
infection in dysplastic lesions indicates that hMLH1-associated
genomic instability and RBSP3-associated cell cycle dysregula-
tion are primary events compared to HPV infection in develop-
ment of the disease. In HPV-positive samples a similar
phenomenon might have occurred through E6- and E7-mediated
degradation of p53 and RB proteins, respectively.(18) However
in expression analysis some samples showed both HPV infec-
tion and also molecular alterations of the candidate TSGs along
with concordant reduced expression. It seems that in these
HPV-positive samples reduced expression of the candidate
TSGs is needed as the expression level of the viral oncoproteins
(E6 ⁄E7) might not be sufficient for induction of the tumori-
genesis.
According to Winberzer et al.(18), the actual the number of
HNSCCs that test positive for HPV-DNA presence far exceedsCancer Sci | June 2010 | vol. 101 | no. 6 | 1517
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Fig. 6. (A) Histogram showing deletion and methylation (a) and the overall alterations (b) in respective tumor suppressor genes in dysplastic
lesions and head and neck squamous cell carcinoma (HNSCC) samples. *P-value significance. (B) Kaplan–Meier 5-year survival probability curves
with cumulative survival of HNSCC patients by alteration (Alt+, alterations; Alt.), no alterations) status in human mismatch repair protein
homologue 1 (hMLH1) (a), RB1 serine phosphates from human chromosome 3 (RBSP3) (b), and Integrin a RLC (ITGA9) (c) loci. Postoperative
overall survival was measured from the date of surgery to the date of last follow-up, known recurrence, or death (up to 5 years). N, total
number of HNSCC samples.
Table 3. Multivariate analysis of overall survival of HNSCC patients
with different clinicopathological parameters
Variable
Overall survival
P-value Hazard ratio 95% CI for HR
hMLH1 alteration 0.014 3.98 1.31 12.12
RBSP3 alteration 0.022 4.43 1.23 15.88
ITGA9 alteration 0.319 0.552 0.172 1.77
Tobacco habit 0.008 7.39 1.65 33.08
HPV infection 0.013 0.229 0.071 0.737
Nodal invasion 0.048 5.07 1.01 25.53
Tumor stage 0.845 0.928 0.441 1.95
Tumor grade 0.129 0.573 0.279 1.17
Age of patients 0.705 0.774 0.207 2.92
CI, confidence interval; hMLH1, human mismatch repair protein
homologue 1; HNSCC, head and neck squamous cell carcinoma; HPV,
human papilloma virus; HR, hazard ratio; ITGA9, integrin a RLC;
RBSP3, RB1 serine phosphates from human chromosome 3.the number that actually express HPV oncoproteins. Only this
latter group of tumors are likely to be HPV induced. Similarly,
alterations of different candidate TSGs like p16, p14, p15, and
p53 were reported to be less frequent in HPV-positive HNSCC
samples.(18,19) The poor patient outcome seen with alterations of1518hMLH1 or RBSP3 suggests their importance as prognostic mark-
ers. Moreover, in the absence of HPV infection, alterations of
these genes could predict adverse prognosis of the patients with
tobacco habit and nodal metastasis. Similarly, adverse prognosis
has been seen in HPV-negative tobacco-habituated HNSCC
patients with alterations in cell cycle regulatory genes like p16
and p53 in the tumors.(18)
Deletion and methylation of hMLH1 have been reported in car-
cinomas of the colon, breast, etc.(8,20,21) However, its association
with the progression of any tumor has not been studied in detail.
Frequent methylation of hMLH1 was seen in dysplastic lesions
and HNSCC samples, though its deletion frequency gradually
increased with tumor progression, indicating the hMLH1 methyl-
ation as an early event in this tumorigenesis. Like our results of
significant association of hMLH1 alterations (deletion ⁄methyla-
tion) with tobacco habit, the association of hMLH1 methylation,
tobacco habit, and genomic instability in HNSCC has been
reported.(7) In addition, hMLH1 was seen to be methylated in
both tumor and adjacent normal tissues of tobacco-habituated
HNSCC patients.(7) This suggests that chronic exposure of
tobacco might create a microenvironment in the exposed cells for
occurrence of genetic ⁄ epigenetic alterations for development of
the disease. The intense nuclear expression of hMLH1 protein in
basal cells of normal epithelium compared to differentiated cells
suggests its role in cellular proliferation and differentiation. In
tumors, reduced nuclear hMLH1 expression concordant withdoi: 10.1111/j.1349-7006.2010.01551.x
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deletion ⁄methylation of the gene might cause genomic tumor
instability.
Similar to our findings, the region harboring ITGA9 has been
demonstrated to be deleted in several epithelial malignancies
including renal, breast, and cervical carcinoma.(10) However,
comparable high frequency of deletion and methylation of the
gene in mild dysplasia indicates its role in the development of
early dysplastic lesions. The ITGA9 is a component of the a9b1
integrin receptor that plays an integral role in different signal
transduction pathways controlling cellular proliferation and dif-
ferentiation.(11) In ITGA9 knockout mice, abnormal proliferation
and differentiation of keratinocytes suggests its role in these cel-
lular processes.(11)
Similar to our results, deletion and methylation of RBSP3 was
reported in breast carcinoma(8) along with deletion in major epi-
thelial malignancies such as those of the lung, renal carcinoma,
etc.,(15) and methylation in acute lymphoid leukemia(22). The
promoter methylation of RBSP3 as suggested in MSRA has been
confirmed by 5-aza-dC experiment in the two oral cancer cell
lines Hep2 and UPCI:SCC084. In addition, frequent inactivation
(8 ⁄11) of RBSP3 due to altered splicing has also been seen in
HNSCC samples; a similar phenomenon has also been reported
in other cancer-related genes, for instance CD44, wilms tumor 1
(WT1), etc.(23) In normal head and neck tissue, the more active
RBSP3B form is abundant, but in tumor, the less active
RBSP3A form is prevalent. RBSP3 removes phosphate group
from serine 807 and 811 of its substrate phosphorylated RB
(pRB), thereby inducing the formation of RB-E2F complex that
blocks the cell cycle at the G1-S boundary.(15) Intense nuclear
staining of pRB in the basal cells of normal epithelium might be
due to low level of expression of RBSP3, and gradual decrease
of pRB expression during differentiation might be indicative of
expressional up-regulation of RBSP3. Thus, RBSP3 plays a cru-Ghosh et al.cial role in controlled cellular proliferation of normal epithe-
lium. In head and neck lesions and the two HNSCC cell lines,
inactivation of RBSP3 due to deletion and ⁄or methylation or
altered splicing might explain strong and homogeneous nuclear
staining of pRB in tumor cells as seen in our immunohistochem-
ical analysis. Accumulation of pRB in the nucleus might provide
selective growth advantage to the transformed cells through
deregulation of the G1-S cell cycle checkpoint, which is consid-
ered as the hallmark of tumor formation.
In summary, it may be concluded that deregulation of multi-
ple cellular pathways such as the hMLH1-associated DNA repair
pathway, ITGA9-associated signaling pathway, and RBSP3–
RB-E2F pathway are needed for the development of early dys-
plastic lesions of the head and neck. The alterations of these
genes might be useful for early diagnosis of the disease.
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Fig. S1. Schematic representation of the integrin a RLC (ITGA9) and RB1 serine phosphates from human chromosome 3 (RBSP3) loci. (a) Illus-
trates the position of ITGA9 probe in intron1 of the gene, D3S3880 localized in the last exon. (b) Location of RBSP3 probe as extending from
upstream, intron1 of the gene locus, D3S4237 was localized in exon 8 of RBSP3.
Fig. S2. Relative expression (mRNA) of two isoforms of RBSP3 (RBSP3A and RBSP3B) in head and neck squamous cell carcinoma (HNSCC)
cell lines (Hep2, UPCI:SCC084, KB, and UPCI:SCC131).
Fig. S3. Immunohistochemical staining patterns of human mismatch repair protein homologue 1 (hMLH1) and phosphorylated RB (pRB) in head
and neck squamous cell carcinoma (HNSCC) cell lines (KB and SCC131) and primary tumors of the head and neck (T). Arrow indicates the
expression pattern of the corresponding proteins.
Table S1. Summary of oligonucleotides used in molecular analysis of the chromosomal 3p22.3 region. (a) Microsatellite markers used in deletion
analysis. (b) Primers used to study hypermethylation profile of the promoter of respective genes. (c) Primers used for mRNA expression study of
the respective genes.
Table S2. Association of data obtained from microsatellite-based and physical mapping techniques.
Table S3. (a) Association of deletion of the candidate tumor suppressor genes (TSGs) in the chromosomal 3p22.3 region. (b) Association of meth-
ylation of the candidate tumor suppressor genes (TSGs) in the chromosomal 3p22.3 region. (c) Association of overall alterations of the candidate
tumor suppressor genes (TSGs).
Table S4. Association of alterations of the candidate tumor suppressor genes (TSGs) with etiological factors (tobacco habit and HPV infection) in
head and neck lesions.
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